Depression
Now accepting patients experiencing sadness, loneliness, feeling blue, having trouble concentrating, and are between the ages 7 and 65.
Depression
Everyone feels stressed or anxious at some point - and almost everyone will feel unhappy with their life or have difficulty sleeping. With depression, this becomes the norm - those suffering from depression find that it's not just an occasional moment where they feel off in one of these ways, but the occasional moment where they don't.
When unhappiness, anxiety, despondency, or any of the side-effects of these feelings start to rule your life, you need to get help - but sometimes that help doesn't make you feel completely better.
Adjunct therapies are designed to be used in addition to an antidepressant that helps, but doesn't alleviate all symptoms of depression. Princeton Medical Institute also offers Transcranial Magnetic Stimulation (TMS) therapy and Ketamine Treatments. Call us today at (609)-921-6050 to see if you qualify for a research study investigating new treatments for depression.
For more information about TMS please visit our site at: http://princetontms.net/index.html
When unhappiness, anxiety, despondency, or any of the side-effects of these feelings start to rule your life, you need to get help - but sometimes that help doesn't make you feel completely better.
Adjunct therapies are designed to be used in addition to an antidepressant that helps, but doesn't alleviate all symptoms of depression. Princeton Medical Institute also offers Transcranial Magnetic Stimulation (TMS) therapy and Ketamine Treatments. Call us today at (609)-921-6050 to see if you qualify for a research study investigating new treatments for depression.
For more information about TMS please visit our site at: http://princetontms.net/index.html
To find out if you qualify, call (609) 921-6050
To find out if you qualify call: (609) 921-6050 or email our Recruitment Team
Trial Identifiers: Stay Tuned for Updates!
Study 1
Who?: Adults age 18 and over diagnosed with Major Depressive Disorder. Seeking patients who are partially satisfied with their current antidepressant treatment.
What?: A phase III study with an investigational drug that is taken in conjunction with patient's current antidepressant medication.
When?: 54 week study, 13 visits
Compensation?: $40 per visit
Chance for Placebo?: 0%, patient is guaranteed to get investigational drug.
What?: A phase III study with an investigational drug that is taken in conjunction with patient's current antidepressant medication.
When?: 54 week study, 13 visits
Compensation?: $40 per visit
Chance for Placebo?: 0%, patient is guaranteed to get investigational drug.
Study 1 - Sponsored by Euthymics Bioscience
Who?: Participants must be 18 to 65 years old and suffering from depression. Other criteria for eligibility will be discussed with interested persons, without obligation, when calling the telephone number listed below.
What?: The purpose of this research study is to test how safe, effective and tolerable an experimental drug called EB-1010 is in patients with major depression. “Experimental” means that the drug has not been approved by the United States Food and Drug Administration (FDA). In this study, EB-1010 will be compared to placebo (a substance that looks like the study drug but has no active ingredients) and to paroxetine (an FDA approved drug) for treating patients with major depression. We are asking you to take part in this study because you are an adult with major depressive disorder who has not had a satisfactory response from your current antidepressant treatment. We want to find out how likely subjects with depression are to have certain side effects during antidepressant treatment.
Compensation?: Compensation will be provided for time and travel.
Chance for Placebo?: 50%
What?: The purpose of this research study is to test how safe, effective and tolerable an experimental drug called EB-1010 is in patients with major depression. “Experimental” means that the drug has not been approved by the United States Food and Drug Administration (FDA). In this study, EB-1010 will be compared to placebo (a substance that looks like the study drug but has no active ingredients) and to paroxetine (an FDA approved drug) for treating patients with major depression. We are asking you to take part in this study because you are an adult with major depressive disorder who has not had a satisfactory response from your current antidepressant treatment. We want to find out how likely subjects with depression are to have certain side effects during antidepressant treatment.
Compensation?: Compensation will be provided for time and travel.
Chance for Placebo?: 50%